Amelyn Rodriguez

Prolonged Low Dose Therapy with a Pan-Deacetylase Inhibtor, Panobinostat (LBH589), in Patients with Myelofibrosis

V. Najfeld, R. Hoffman, J. Goldberg, 2011 .

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study

Sonali M. Smith, J. Leonard, P. Christos, 2020 .

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.

Sonali M. Smith, J. Leonard, W. Tam, 2018, Blood.

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

Sonali M. Smith, J. Leonard, P. Christos, 2015, The New England journal of medicine.

Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report

Sonali M. Smith, J. Leonard, P. Christos, 2014 .

A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).

V. Najfeld, R. Hoffman, J. Goldberg, 2009 .

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

Sonali M. Smith, J. Leonard, P. Christos, 2015, The New England journal of medicine.

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

O. Elemento, J. Leonard, S. Chen‐Kiang, 2022, Blood.